Dr. Christine Munz becomes CEO at Eppendorf
![](/fileadmin/_processed_/7/e/csm_Portrait_Christine_Munz_91e0b646d3.jpg)
> Dr. Christine Munz appointed as CEO
> Dr. Wilhelm Plüster completes term in office as planned
Hamburg, August 30, 2024 – The Supervisory Board of Eppendorf SE has appointed Dr. Christine Munz as the new CEO of the Eppendorf Group. On October 1, 2024, she will succeed Dr. Wilhelm Plüster who will now take on other strategically relevant responsibilities in the company as planned.
“We are very pleased that we were able to win Dr. Munz for Eppendorf and the CEO position,” said Philipp von Loeper, the Chairman of the Supervisory Board at Eppendorf SE. “On behalf of the entire Supervisory Board, I would also like to thank Dr. Plüster for his tremendous commitment to the company with which he has worked as CEO in the past few months. After serving more than 10 years on the Management Board of Eppendorf, he demonstrated once again his enormous dedication to the company. We are really pleased that he will remain at Eppendorf and assume another responsible position within the company.”
With Dr. Christine Munz Eppendorf will have a strong international experienced CEO, said von Loeper and added: “She is a proven and highly skilled manager with many years of experience in the life science industry. Working together with the global management team, Dr. Munz will continue to drive forward Eppendorf’s successful activities and expand them in a targeted manner.”
About the Eppendorf Group
Eppendorf is a leading international company in the life science industry that develops, produces and markets devices, consumables and services used in laboratories around the world.
The product portfolio is divided into four core business areas: Liquid Handling, Consumables, Separation & Instrumentation and Bioprocess. It includes pipettes, pipette tips, centrifuges, mixers, ultra-low-temperature freezers and bioreactors used in cell and genetic research. In addition, Eppendorf offers a wide variety of high-quality consumables. In fiscal year 2023, the Eppendorf Group generated sales of 1.08 billion euros and invested 69 million euros in research and development (R&D).
Eppendorf products are used in academic and commercial research laboratories, e.g., in companies from the pharmaceutical and biotechnological as well as the chemical and food industries. They are also used in laboratories that perform clinical or environmental analysis, in forensic laboratories and in industrial laboratories where process analysis, production and quality assurance are performed.
Eppendorf was established in 1945; is based in Hamburg, Germany; operates production and R&E facilities in Europe, Asia and North America; and owns subsidiaries in 32 countries. The Group employs more than 5,000 people around the world. They all work to fulfill the mission of the company’s founders: to improve human living conditions.
Media contact:
Dr. Ralph Esper
Eppendorf SE
Barkhausenweg 1
22339 Hamburg
Phone: +49 40 538 01-195
Cell: +49 170 79 80 778
Email: esper.r@eppendorf.de